Transforming discovery with accelerated synthesis, validation, and production of specific nucleic acid therapies.
Cloning-free approach using our platform for rapid target discovery and validation: design, build, test, and learn.
Improved specificity and transport, low off-target effects, multiplexing and multidimensional target validation.
Scalable and high-throughput
Using state-of-the art bioinformatics toolbox and AI tools, we create Nanoligomers to target canonical pathways and upstream regulators to create the best-in-class and first-in-class therapies.
Low-cost scalable chemistry allows synthesis of hundreds of molecules within days.
Using same peptide chassis ensures synthesis of multiple therapeutic molecules in the same manufacturing facility with the need to re-tool. This makes Nanoligomers ideal for Precision and Personalized medicine.
Nanoligomers offer small-molecule like transport, without the need for any lipid encapsulation or special formulation.
Nanoligomers can be directly administered using multiple routes of administration and are shown to be safe and effective in multiple pre-clinical studies.
For treatments being developed against neurodegenerative diseases, Nanoligomer have shown the capability to cross the blood-brain barrier when intended.